Thirty-two male mice were started on a 60% high-fat diet of 5.24 kcal/g at three weeks of age for 19 weeks, followed by a 45% HFD of 4.73 kcal/g for six additional weeks
Higher concentrations may increase results but also increase irritation risk
Finally, the lack of detailed reasons for redialysis or mortality also constrains the depth of our outcome analysis, In summary, our observations suggest that GLP-1 RAs may be associated with a reduction in the risk of mortality, MACEs, and MAKEs in patients with type 2 diabetes following severe AKI, over a median follow-up of 2.3 years
GLP-1 receptor agonists approved for use in the UK include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia)
For more information on Numerators GLP-1 insights and offerings, head over to our GLP-1 Research Hub or get in touch with our team.
Talsania, T